Quanterix, PreludeDX highlights AidaBREAST multi-omic assay

PreludeDx and Quanterix (QTRX) Corporation highlighted that AidaBREAST, a multi-omic assay made to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, which was developed on Akoya PhenoImager HT platform using Opal chemistry. The validation of AidaBREAST included 922 hormone receptor-positive, HER2-negative invasive breast cancer patients across four academic and clinical centers in the United States and Sweden, with a median follow-up of ~10 years. The study demonstrated the test to be both prognostic for 10-year locoregional recurrence risk and predictive for radiation therapy benefit, two capabilities not previously available to clinicians in a single assay for early-stage invasive breast cancer. AidaBREAST leverages the PhenoImager HT platform and Opal chemistry to obtain spatial multiplex protein expression, which is then integrated with targeted next-generation RNA sequencing for comprehensive assessment of tumor biology. “AidaBREAST harnesses the power of spatial biology and AI to provide unique insights into the tumor and immune-microenvironment not available from clinicopathology,” said Karuna Mittal, PhD, Senior Director of Research and Development at PreludeDx and co-author of the published study. “For the first time, oncologists have a tool that tells them not just how likely a patient is to recur, but whether radiation therapy is actually going to help that specific patient. That is a meaningful shift in how we can better inform treatment decisions.”